Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Venous Thromboembolism

65 clinical trials

45 products

5 drugs

Clinical trial
Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Dabigatran Etexilate
Product
Abelacimab
Clinical trial
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Apixaban
Clinical trial
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Dalteparin
Clinical trial
A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)
Status: Not yet recruiting, Estimated PCD: 2026-06-08
Product
REGN7508
Product
REGN9933
Product
Placebo
Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty
Status: Active (not recruiting), Estimated PCD: 2024-05-29
Product
Apixiban
Product
Enoxaparin
Clinical trial
Special Drug Use Investigation of Rivaroxaban in Pediatric Patients With Congenital Heart Disease (CHD) Who Had Undergone the Fontan Procedure
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Rivaroxaban
Product
apixaban
Product
warfarin
Clinical trial
Post-Discharge Treatment Patterns and Outcomes in Patients With Venous Thromboembolism
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)
Status: Completed, Estimated PCD: 2022-05-24
Product
Edoxaban
Product
Standard of Care
Clinical trial
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients
Status: Completed, Estimated PCD: 2021-09-16
Clinical trial
Descriptive Analysis of VTE Treatment With Rivaroxaban in Japanese Clinical Practice Using a Claims Database
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea
Status: Completed, Estimated PCD: 2021-09-30
Product
Dabigatran
Clinical trial
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Status: Completed, Estimated PCD: 2015-12-01
Product
dabigatran
Clinical trial
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Status: Completed, Estimated PCD: 2022-03-31
Product
Low molecular weight heparin
Product
Direct Oral Anticoagulants
Clinical trial
COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.
Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery
Status: Terminated, Estimated PCD: 2011-12-21
Product
Betrixaban
Product
Parenteral anticoagulant
Product
Warfarin
Clinical trial
Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban (H2H-OSCAR-US)
Status: Completed, Estimated PCD: 2022-10-05
Clinical trial
A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)
Status: , Estimated PCD: 2026-11-01
Product
Thrombate
Clinical trial
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-10-01
Drug
Rivaroxaban
Product
Nadroparin
Clinical trial
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients
Status: Completed, Estimated PCD: 2022-03-10
Product
Unfractionated Heparin
Clinical trial
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
Status: Recruiting, Estimated PCD: 2027-06-30
Product
Oxygen
Clinical trial
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS): A Pilot Study
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Clopidogrel
Clinical trial
Randomized Controlled Trial of Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Tinzaparin Sodium
Clinical trial
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Product
Colchicine
Clinical trial
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
Prevention of Thromboembolism With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
Status: Terminated, Estimated PCD: 2021-11-11
Drug
apixaban
Clinical trial
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women
Status: Completed, Estimated PCD: 2020-02-13
Clinical trial
The Exploratory Study on Clinical Rational Use of Rivaroxaban Dosing in Elderly Chinese Population
Status: Recruiting, Estimated PCD: 2026-09-30
Product
Direct oral anticoagulant
Clinical trial
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Status: Completed, Estimated PCD: 2020-10-31
Clinical trial
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
Status: Completed, Estimated PCD: 2023-11-08
Product
DOAC
Clinical trial
Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism: Pilot Randomized Study (RADIANT Study)
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
Omeprazole
Clinical trial
The Role of Platelet TLRs in Platelet Activation During VTE
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Blood sample
Clinical trial
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty (EPCATIII)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Rivaroxaban + Acetylsalicylic acid
Product
Acetylsalicylic acid
Clinical trial
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.
Status: Recruiting, Estimated PCD: 2025-03-01
Drug
Aspirin
Clinical trial
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Status: Not yet recruiting, Estimated PCD: 2026-09-30
Product
Anticoagulant
Clinical trial
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
PET Fibrin Imaging of DVT and PE
Status: Recruiting, Estimated PCD: 2024-06-01
Product
64Cu-FBP8
Clinical trial
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Status: Recruiting, Estimated PCD: 2025-12-21
Clinical trial
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
Status: Completed, Estimated PCD: 2019-06-30
Clinical trial
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial
Status: Recruiting, Estimated PCD: 2026-05-01
Drug
Varlilumab
Clinical trial
2012-30
Status: Completed, Estimated PCD: 2016-07-18
Product
Extra Blood Draw
Clinical trial
A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin in Postpartum Women at Risk of Developing Venous Thromboembolism
Status: Completed, Estimated PCD: 2023-09-05
Product
Aspirin
Clinical trial
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism
Status: Terminated, Estimated PCD: 2023-11-30
Clinical trial
Cluster-randomized Trial of Low Molecular Weight Heparins - Directly Through EPIC
Status: Recruiting, Estimated PCD: 2025-03-23
Product
Tinzaparin
Clinical trial
A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Rosuvastatin
Clinical trial
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
Tranexamic acid
Clinical trial
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-03-13
Clinical trial
STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown
Status: Terminated, Estimated PCD: 2021-05-24
Product
Aspirin and Rosuvastatin
Clinical trial
The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)
Status: Terminated, Estimated PCD: 2023-03-02
Product
Anticoagulant drugs
Clinical trial
Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-07-13
Clinical trial
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Low Molecular Weight hEparin vs. Aspirin Post-partum
Status: Recruiting, Estimated PCD: 2024-02-29
Product
Prophylactic low molecular weight heparin
Product
Low molecular weight heparin + Low-dose aspirin
Clinical trial
A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast Reconstruction
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer
Status: Terminated, Estimated PCD: 2021-09-01
Clinical trial
Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment
Status: Recruiting, Estimated PCD: 2025-07-01
Drug
Anticoagulants
Clinical trial
Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
Post-Marketing Database Study for Rivaroxaban in Patients With Pediatric VTE
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
Status: Not yet recruiting, Estimated PCD: 2025-03-26